tility of [11C]4DST PET in assessing malignancy of tumors
Phase 2
- Conditions
- Brain tumor, head and neck tumor, lung cancer, liver carcinoma, biliary tract cancer, pancreas cance
- Registration Number
- JPRN-jRCTs031180299
- Lead Sponsor
- Saginoya Toshiyuki
- Brief Summary
[11C]4DST PET/CT was able to detect various type of malignant tumors.FDG-PET/CT has dissociation in accumulation and the clinical significance of the difference is an issue for the future.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
1.Patients who have malignant tumors or are suspected to have malignant tumors.
2.Patients who agree and write informed consent form.
Exclusion Criteria
1.Patients who are assumed to be difficult to implement the PET/CT examination due to general condition etc.
2.Women who are pregnant
3.Other patients who are judged inappropriate by researcher, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method [11C]4DST uptake in tumors(visual assessment, SUV quantification, uptake count)
- Secondary Outcome Measures
Name Time Method 1.Histological malignancy<br>2.FDG uptake in tumors